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(57) ABSTRACT 
Methods for treating maladies Such as cutaneous vascular 
lesions. A patient in need of vascular lesion treatment is 
identified. A hyperoSmotic agent is administered to a region 
adjacent the lesion. Blood flow velocity is slowed within the 
region using the hyperosmotic agent, and the lesion is 
exposed to laser radiation. 
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LASER TREATMENT OF CUTANEOUS 
WASCULAR LESIONS 
This application claims priority to, and incorporates by 
reference, U.S. Provisional Patent Application Ser. No. 
60/363,726 filed Mar. 12, 2002 entitled “Laser Treatment of 
Cutaneous Vascular Lesions.” 
BACKGROUND OF THE INVENTION 
Aspects of this invention were made with government 
Support of the National Science Foundation, grant number 
BES998.6296. Further support has been provided by Texas 
Higher Education Coordinating Board, grant number BER 
ATP-253. Accordingly, the government may have certain 
rights in this invention. 
1. Field of the Invention 
The present invention relates generally to biomedical 
engineering, imaging, medicine, and medical treatment. 
More particularly, it concerns clinical laser treatment of 
cutaneous vascular lesions using chemical agents that not 
only increase light penetration but also decrease blood flow 
Velocity. 
2. Description of Related Art 
Cutaneous vascular lesions can be classified into two 
main categories. The first includes benign disorders, Such as 
the hemangioma (a benign tumor consisting of a dense mass 
of blood vessels) and the cutaneous nevus (a congenital 
discoloration of a skin area, also called a Strawberry or Stork 
mark) van Gemert et al., 1995; Mulliken, 1992). The second 
category is made up of vascular malformations, where the 
lesion is caused by abnormal blood vessel pathology 
Mulliken, 1992). Included in this class of cutaneous vas 
cular lesions is the port wine stain (PWS), a congenital 
lesion in which ectatic capillaries make an area appear a dark 
red color and produce raised nodules protruding above the 
normal skin Surface. Another vascular malformation is leg 
telangiectasia, Small, localized clusters of blood vessels 
Sometimes found deep (millimeters) below the Surface. 
Telangicctasis can also occur as an extensive network that is 
much more widespread Goldman, 1992). 
Some of these lesions, such as the port wine stain (PWS), 
can be quite traumatic for a patient, resulting in Serious 
psychological and Social problems Lanigan et al., 1989; 
Tan, 1992; Morelli et al., 1992; Masciarelli, 1992; van 
Gemert, 1992). When lesions are located near joints, lips, or 
the eyes they can also interfere with normal functions and 
lead to Serious problems Such as hypertrophy of skeletal 
tissue or more severe conditions Mulliken, 1992). Because 
the lesions become increasingly hypertrophic, early treat 
ment is preferred. 
Currently, the only accepted treatment for these vascular 
lesions is pulsed laser radiation at Selected wavelengths that 
target the absorption characteristics of hemoglobin. By 
Selecting the proper laser pulse duration, the process is 
referred to as selective photothermolysis. Blood vessels are 
damaged by the increase in temperature resulting from 
absorption of pulsed laser light. The objective is to perma 
nently destroy the blood vessels comprising a cutaneous 
lesion, while sparing Surrounding skin Structures. 
A number of Shortcomings exist in current clinical treat 
ments due to the lack of parameter optimization and Suffi 
cient delivery of light to deep lying blood vessels. 
Unfortunately, because the treatment parameters governing 
the effectiveness of laser therapies vary greatly from patient 
to patient, many instances of incomplete destruction of 











In general, low treatment Success rates remain a problem 
with existing laser treatments of vascular lesions. This low 
Success rate is due to at least two main limitations: (a) 
restrictions in the achievable penetration depth of light in 
biological tissue and (b) insufficient increase in blood vessel 
temperatures associated with high flow velocities. 
The first limitation (limitation (a)) in the laser treatment of 
cutaneous vascular lesions involves rapid attenuation of 
incident light with depth. Attenuation of laser light in 
biological media occurs by absorption and Scattering. In 
many cases, deep blood vessels in a lesion are not Suffi 
ciently heated by incident light due to competition from 
absorption and Scattering by other tissue constituents. This 
competition for laser light decreases the fluence rate 
W/cm) available for photocoagulation of a blood vessel. In 
View of this limitation, methodologies that decrease light 
attenuation and increase the penetration depth of incident 
light are desirable. 
The second limitation (limitation (b)) in the laser treat 
ment of vascular lesions involves the lack of control of blood 
flow velocity. Blood flow velocity has been shown to be an 
important factor that affects the Success of vessel photoco 
agulation. Specifically Boergen, et al. have shown that 
complete flow cessation of blood in vessels before laser 
irradiation significantly decreases the fluences required to 
permanently destroy a blood vessel Boergen et al., 1977). 
Despite this realization, current laser treatment techniques 
have not been able to fully capitalize upon the benefits 
afforded by controlling blood flow velocity during treat 
ment. In View of this limitation, methodologies that not only 
decrease light attenuation, but also decrease blood flow 
velocity would be desirable. 
The referenced shortcomings of conventional methodolo 
gies mentioned above are not intended to be exhaustive, but 
rather are among many that tend to impair the effectiveness 
of previously known techniques concerning the laser treat 
ment of cutaneous vascular lesions. Other noteworthy prob 
lems may also exist; however, those mentioned here are 
Sufficient to demonstrate that methodology appearing in the 
art have not been altogether Satisfactory and that a signifi 
cant need exists for the techniques described and claimed 
herein. 
SUMMARY OF THE INVENTION 
Shortcomings of the prior art are reduced or eliminated by 
the techniques disclosed herein. These techniques are appli 
cable to a vast number of applications, including but not 
limited to applications involving the laser removal of cuta 
neous vascular lesions. 
Procedures described herein are able to reduce the laser 
dose required for irreversible photocoagulation of blood 
vessels in tissue. Each of the two main limitations of 
conventional techniques, discussed above, are addressed by 
using a specific class of chemical agents together with 
application of laser radiation to blood vessels. Required 
fluences for the permanent destruction of blood vessels in 
the skin are significantly lower with the techniques of this 
disclosure as compared to cases where no chemical agents 
are used. Experimental results Substantiating the assertions 
of this disclosure are presented in the Examples Section. 
In a recent Study, the inventors discovered that the addi 
tion of glycerol, and other chemical agents, to Skin leads to 
changes in blood vessel morphology. In particular, glycerol 
alters the flow characteristics of blood in the skin. In the 
Study, glycerol was added to the Subdermal side of skin in 
which blood vessels were located 80-100 um from the 
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subdermal Surface. Within twenty minutes, the flow in 
venules (approximately 100-400 um in diameter) ceased. 
Over prolonged periods of exposure to glycerol, flow in 
arterioles ceased as well. When the skin was hydrated in a 
physiologic Saline Solution, flow in arterioles and Venules 
returned to physiologic values. In the experience of the 
inventors, the addition of glycerol, and the other hyperOS 
motic agents described herein, to blood vessels did not result 
in any permanent vessel damage. 
These recently-discovered morphological effects of glyc 
erol (and other agents) on blood flow velocity, coupled with 
glycerol's ability to increase light transmission within turbid 
media (i.e., glycerol’s “optical clearing properties), Serve as 
one basis for an effective, new methodology for vastly 
improved laser treatment of cutaneous vascular lesions. 
First, increased light penetration due to glycerol and other 
hyperoSmotic agents allows for better localization of light on 
deep blood vessels that previously would not have been 
targeted. Second, decrease in blood flow Velocity due to 
glycerol allows for Significantly lower radiant light expo 
Sures to be used for blood vessel photocoagulation. 
In one embodiment, the invention is a method for reduc 
ing the amount of radiation required to destroy a blood 
vessel of a cutaneous vascular lesion. The method involves 
administering a hyperoSmotic agent to the blood vessel to 
Slow blood flow velocity prior to exposure to laser radiation. 
In another embodiment, the invention is a method of 
treating a cutaneous vascular lesion. A patient in need of 
vascular lesion treatment is identified. A hyperoSmotic agent 
is administered to a region adjacent the lesion. Blood flow 
Velocity is slowed within the region using the hyperosmotic 
agent, and the lesion is exposed to laser radiation. 
In another embodiment, the invention is a method of 
destroying a blood vessel. A hyperoSmotic agent is admin 
istered to the blood vessel to reduce blood flow velocity by 
at least 15%, and the blood vessel is exposed to an amount 
of laser radiation at least 15% less than an amount of 
radiation required to destroy a blood vessel in the absence of 
the administration of the hyperoSmotic agent. 
AS used herein, “amount of radiation” Simply means any 
measure of radiation being used to treat a lesion or other 
malady. In one embodiment, the “amount of radiation' may 
be measured with reference to energy per unit area, Such as 
J/cm°. As used herein, “adjacent” shall be interpreted 
broadly to mean not only “close to,” but also overlapping 
with (completely or partially). Thus, an agent administered 
“adjacent a region may be administered near or at that 
region. 
Other features and asSociated advantages will become 
apparent with reference to the following detailed description 
of Specific embodiments in connection with the accompa 
nying drawings. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present Specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of Specific 
embodiments presented herein. 
FIG. 1 is a flowchart illustrating exemplary embodiments 
of the present disclosure. 
FIGS. 2A and 2B are photographs in accordance with 
embodiments of the present disclosure. Preparation of a 











shown. Blood vessels are located approximately 80-100 um 
from the near-Surface. FIG. 2A shows native skin. FIG. 2B 
shows the Same window preparation, twenty minutes fol 
lowing treatment with glycerol. 
FIG. 3 is a photograph in accordance with embodiments 
of the present disclosure. The locations of subdermal blood 
vessel irradiations in one dorsal Skin flap window 
preparation are shown. 
FIG. 4 is a graph showing results in accordance with 
embodiments of the present disclosure. This figure shows 
RE50 (radiant exposures which have been found through 
statistical analysis of the experimental data to result in a 50% 
probability of permanent vessel coagulation) values for 
permanent blood vessel coagulation using a 532 nm laser 
(10 ms pulse duration, 3 mm spot size) applied to the 
Subdermal side of skin. Two experimental conditions are 
represented in this plot. Subdermal irradiations on native 
skin are Summarized in the “native venules” and “native 
arterioles' data points. Subdermal irradiations conducted on 
skin in which anhydrous was applied to the Subdermal side 
are shown by the “glycerol venules” and “glycerol arteri 
oles' points. 
FIG. 5 is a Schematic diagram of equipment Suitable for 
carrying out embodiments of the present disclosure. 
FIGS. 6A and 6B are photographs in accordance with 
embodiments of the present disclosure. Shown are ampli 
tude (FIG. 6A) and Doppler (FIG. 6B) images of skin in the 
hamster dorsal skin flap window-preparation. The skin 
shown is a control Sample prior to irradiation. The Surface at 
the top is the Subdermal connective tissue. 
FIGS. 7A and 7B are photographs in accordance with 
embodiments of the present disclosure. Shown is the Sub 
dermal side of the control Sample twenty-four hours after 
irradiations (applied to the epidermal Surface) up to 16 
J/cm. FIG. 7A is an amplitude image, and FIG. 7B is a 
Doppler image. Flow in both the arteriole and venule 
remains. 
FIGS. 8A and 8B are photographs in accordance with 
embodiments of the present disclosure. Shown are ampli 
tude (FIG. 8A) and Doppler (FIG. 8B) images of a native 
skin Sample imaged from the Subdermal side. An arteriole 
and Venule are identified in the Doppler image. 
FIGS. 9A and 9B are photographs in accordance with 
embodiments of the present disclosure. Shown are ampli 
tude (FIG. 9A) and Doppler (FIG. 9B) images of a skin 
Sample treated with glycerol for twenty minutes and imaged 
from the Subdermal side. The arteriole and venule are 
identified in the amplitude image; however, no flow remains 
as can be seen from the lack of Doppler shifts in the Doppler 
image. 
FIGS. 10A and 10B are photographs in accordance with 
embodiments of the present disclosure. Shown are ampli 
tude (FIG. 10A) and Doppler (FIG. 10B) images showing 
hamster skin twenty-four hours after irradiation with 1.6 
J/cm following treatment with glycerol. Permanent coagul 
lation has been achieved in both blood vessels. 
DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
U.S. Pat. No. 6,275,726 (“the 726 patent”) entitled, 
“Methods of enhanced light transmission through turbid 
biological media” by Chan et al. is hereby incorporated by 
reference in its entirety. 
The 726 patent involves a process to increase light 
transmission in biological tissue. The technique involves 
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temporarily replacing tissue water with a fluid that has a 
refractive indeX closer to that of inter/intra cellular compo 
nents. Subsequently, the amount of indeX mis-match 
between those components and the fluid environment is 
temporarily decreased. This, in turn, lowers the amount of 
random reflection and refraction which also reduces light 
Scattering. 
Although useful for the methodology it describes and 
claims, the 726 patent does not address problems associated 
with conventional laser techniques inability to adequately 
control blood flow velocity. This inability, in turn, hinders 
the effective clinical laser treatment of cutaneous vascular 
lesions. Further, the 726 patent does not recognize that 
certain chemical agents may significantly affect blood flow 
Velocity in a manner that can be exploited to greatly improve 
the treatment of cutaneous vascular lesions. In Sum, the 726 
patent does not recognize or describe the particular appli 
cations described and claimed herein that create a new 
clinical laser treatment protocol for cutaneous vascular 
lesions. This protocol not only reduces light attenuation but 
also controls blood flow velocity to effectively remove 
lesions using lasers exhibiting lower radiant light exposures. 
The present disclosure describes methods for the laser 
treatment of cutaneous vascular lesions and other maladies. 
The techniques described herein are advantageous at least 
because they address Shortcomings exhibited in the prior 
art-(a) light attenuation and (b) lack of control of blood 
flow velocity. Applications for these techniques are vast and 
include any situation in which a decreased blood flow 
Velocity and/or reduced light attenuation is desired. In 
particular, the laser treatment of blood vessel lesions, includ 
ing hyper-vascular lesions, benefits greatly. Examples of this 
type of treatment are port wine Stains and leg telangiectasia. 
One aspect of embodiments of this disclosure involves the 
use of chemical agents to alter the optical properties of tissue 
in order to enhance the delivery of light to physiological 
targets in the skin (i.e., "optical clearing”). This aspect is 
based, at least in part, upon the findings of U.S. Pat. No. 
6,275,726, which has been incorporated by reference and 
discusses how appropriate chemical agents may be used to 
optically alter biological tissue in a direction that increases 
the penetration-depth of light. 
Another aspect of embodiments of this disclosure 
involves the use of chemical agents to alter the blood flow 
Velocity of tissue. The chemical agents allow one to control 
the blood flow velocity; in particular, it has recently been 
discovered by the inventors that the application of appro 
priate agents may significantly reduce, or even halt, blood 
flow velocity in a reversible manner. 
In combination, these two aspects, which would have 
Seemed to be disparate and unrelated phenomena prior to 
this disclosure, provide the basis for drastically improved 
laser treatment techniques. Specifically, these two aspects in 
combination provide for an effective clinical laser treatment 
protocol for the removal of cutaneous vascular lesions. 
In one embodiment, hyperoSmotic chemical agents are 
used to Significantly reduce the laser doses required to 
irreversibly destroy blood vessels of a vascular lesion. The 
method uses chemical agents that temporarily reduce Scat 
tering in biological tissue and reduce the Velocity of blood 
in Vessels. Based on the experimental results listed in the 
“Examples' Section of this disclosure, a significant improve 
ment in clinical treatment of hyper-vascular lesions is pro 
Vided. In particular, the results reveal a significant reduction 
in the laser radiant exposures required to permanently 












tions and when the laser beam is delivered to the skin 
epidermal Surface and must travel through the dermis to 
reach blood vessels. 
Different embodiments involve the application of differ 
ent hyperoSmotic chemical agents prior to laser irradiation 
of a vascular lesion. In one embodiment, a Suitable hyper 
oSmotic chemical agent is glycerol. In other embodiments, 
Suitable hyperoSmotic chemical agents may include, but are 
not limited to: dimethyl Sulfoxide, Sucrose, glucose 
(dextrose), propylene glycol, polyethylene glycol, hypague 
Sodium (diatrizoate Sodium), or mannitol. Any of these 
agents may be used alone, or in combination with another 
one or more of the agents. 
Suitable doses and concentrations of hyperosmotic 
chemical agents may be found by reference to U.S. Pat. No. 
6,275,726. In different embodiments, agents may be diluted 
and Still achieve the same or Similar results discussed herein; 
in particular, in different embodiments, one may dilute 
glycerol (down to 25%) or glucose (down to 10%). 
Suitable techniques to deliver the hyperoSmotic chemical 
agents may be found by reference to U.S. Pat. No. 6,275, 
726, although it will be understood that any other suitable 
delivery technique may be exploited including, but not 
limited to, a variety of transdernal techniques. One Suitable 
technique for delivery is injection. In different embodiments, 
the injection may be accomplished by a fine hypodermic 
needle or a high Velocity jet. Another Suitable technique 
involves use of a transdermal drug delivery device. Such 
Suitable techniques include, but arc not limited to: (1) tape 
Stripping the Surface of skin to remove a Small area of 
epidermis (a technique in common use), (2) use of ablative 
methods-Such as laser ablation techniques-to create 
micro-holes in the skin down to the dermis or subdermis, (3) 
chemical peels, (4) mechanical debridement, (5) ultrasound 
enhanced techniques, (6) electroporation, or (7) iontophore 
sis to aid transdermal diffusion of chemical agents. 
After the desired optical and morphological changes are 
induced on the tissue through the delivery and application 
(e.g., transdermal delivery or injection) of one or more 
hyperosmotic chemical agents, laser radiation may be 
applied to the lesion. The chemical agents both reduce 
Scattering in the biological tissue, and also lead to the 
reduction and/or cessation of flow in arterioles and Venules. 
The changes allow laser energy to be more directly applied 
to the vessels and, concurrently, reduce the required energy 
to destroy a given vessel. 
Accordingly, the techniques of this disclosure Solve the 
once-difficult balancing problem of being able to deliver 
Sufficient laser energy to a targeted blood vessel to destroy 
the vessel without damage to the epidermis and dermis by 
making it possible to use lower power lasers (and/or lower 
laser doses) to cause irreversible photocoagulation. The 
techniques reduce or even eliminate the necessity of mul 
tiple treatments to coagulate vessels. Advantageously, the 
observed optical, morphological, and physiological effects 
due to application of the chemical agents to skin are revers 
ible with simple hydration of the tissue. 
Turning to FIG. 1, there is shown a flowchart illustrating 
general, exemplary embodiments of the present disclosure. 
In step 20, a patient is identified. In one embodiment, the 
patient may be in need of vascular lesion treatment. In other 
embodiments, the patient may be in need of other treatments 
that would benefit from a reduction in light reflection/ 
refraction and/or decreased blood flow velocity. In one 
embodiment, the patient may be human, while in other 
embodiments, the patient may be any other type of living 
organism. 
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In Step 30, one or more hyperoSmotic agents are admin 
istered to the patient. In the case of vascular lesions, an agent 
is administered to a region adjacent the lesion-at the lesion 
itself or near the region. In one embodiment, the agent may 
be administered at the site of one or more blood vessels to 
be permanently photocoagulated, or destroyed, by laser 
treatment. The administration of the agent may be done as is 
known in the art. In one embodiment, injection by a hypo 
dermic needle or a high Velocity jet may be used. In other 
embodiments, tape Stripping, ablation, chemical peel, 
electroporation, iontophoresis, mechanical debridement, or 
other transdermal delivery method may be used. The hyper 
oSmotic agent may include any of the agents discussed 
herein, including those discussed in U.S. Pat. No. 6,275,726. 
In step 40, blood flow velocity is reduced by way of the 
administration of the hyperosmotic agent. In one 
embodiment, this reduction in blood flow velocity may be at 
least 15%. In particular, the reduction in blood flow velocity 
may be about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 
23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 
33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 
43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 
53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 
63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 
73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 
93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. To 
measure the reduction in blood flow velocity, one may 
measure the blood flow velocity before and after application 
of a hyperoSmotic agent. 
In step 50, light reflection and refraction are reduced 
among cellular components at or about a region to be treated 
to enhance light transmission. This "optical clearing comes 
about by way of the administration of the hyperosmotic 
agent, as discussed in U.S. Pat. No. 6,275,726. 
In Step 60, the area to be treated is exposed to radiation, 
Such as laser radiation. The amount of radiation applied to 
the area may vary greatly depending upon the application. In 
embodiments involving the treatment of cutaneous vascular 
lesions, the administration of one or more hyperoSmotic 
agents in Step 30 advantageously lowers the amount of 
radiation required to treat the lesions (i.e., to permanent 
photocoagulate, or destroy, blood vessels associated with the 
lesions). In fact, the reduction in laser radiation may be at 
least 15%. In particular, the reduction in radiation amount 
may be about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 
23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 
33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 
43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 
53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 
63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 
73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 
93%, 94%, or 95%. To measure the reduction in blood flow 
Velocity, one may measure the energy per area required to 
treat a lesion with and without the administration of a 
hyperoSmotic agent. In one embodiment involving the treat 
ment of lesions, a Suitable range of radiation may be 
between about 0.1 and about 20 J/cm’. In one embodiment, 
the Source of laser radiation may be light Sources, including 
lasers, in the wavelength range of about 450-1100 nm. 
Typical Sources include, but are not limited to cw 
(continuous wave) and pulsed diode lasers, dye lasers, Solid 
State lasers, and gas lasers. In one embodiment delivery may 
be through optical fibers. In other embodiments, any other 
Suitable Source of radiation may be used. 
In Step 70, a hydrating agent is administered to the area 











the hyperoSmotic agent from the area and to return the area 
being treated as close as possible back to its normal, 
pre-treatment State, excluding the Status of blood vessels. 
The administration of the hydrating agent may be accom 
plished by any of the means used to administer the hyper 
osmotic agent(s), including injection. In one embodiment, 
the hydrating agent may include Saline. Other hydrating 
agents and techniques are discussed in U.S. Pat. No. 6,275, 
726. 
FIG. 5 shows one suitable apparatus for visualizing the 
effects of the techniques described herein, Such as those 
illustrated in FIG. 1. FIG. 5 shows an optical setup of a color 
Doppler optical coherence tomography system (CDOCT). 
CDOCT is a light imaging device that acquires croSS 
Sectional, in-depth images of biological tissue Izatt et al., ). 
Besides providing images of tissue structure, CDOCT 
reveals blood vessels by detecting Doppler shifts due to 
moving blood. After imaging, Samples may be irradiated in 
place using equipment Such as a frequency-doubled 
Nd:YAG laser (Vcrsapulse V, Coherent). Technical specifi 
cations of the device are described: A Superluminescent 
diode (SLD) centered at 1290 nm is used as the light source. 
The light from the SLD is split into a reference arm (incident 
on a reference mirror) and a sample arm (incident on the 
Sample). The probing beam is incident on the dorsal window, 
which may be tilted at 201t with respect to the vertical to 
obtain Doppler information. The light from the sample and 
the reference mirror recombine and form an interference 
Signal. The envelope of the interference Signal may be 
filtered with a bandpass filter (BPF). The signal is coherently 
demodulated in a lock-in amplifier. The backScattered mag 
nitude (I) and the phase information (Q) undergo digital 
signal processing in a computer. Labview Software IZatt, 
Case Western University may be used to process and 
display amplitude (magnitude) and Doppler (velocity) 
images. 
With the benefit of the present disclosure, those having 
skill in the art will comprehend that techniqueS claimed 
herein and described above may be modified and applied to 
a number of additional, different applications, achieving the 
Same or a similar result. The claims attached hereto cover all 
such modifications that fall within the scope and spirit of this 
disclosure. 
The following examples are included to demonstrate 
Specific embodiments of this disclosure. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples that follow represent techniques 
discovered by the inventors to function well in the practice 
of the invention, and thus can be considered to constitute 
Specific modes for its practice. However, those of skill in the 
art should, in light of the present disclosure, appreciate that 
many changes can be made in the Specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the Spirit and Scope of the invention. 
EXAMPLES 
In these examples, the inventors use chemical agents for 
reducing the applied laser radiant exposure required to 
permanently destroy blood vessels. The technique has been 
demonstrated both in direct blood vessel irradiations, and 
also on blood vessels located hundreds of microns beneath 
the epidermal Surface of in Vivo skin. Evidence is presented 
that demonstrates the treatment of skin with agents Such as 
glycerol prior to laser radiation leads to a significant 
decrease in the delivered radiant exposures required to 
permanently destroy a blood vessel, compared to control 
cases where treatment with agents Such as glycerol did not 
OCC. 
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MATERIALS AND METHODS 
Animal Model 
Hamsters were anesthetized with a 4:3 mixture of Ket 
amine (20 mg/ml):Rompun (100 mg/ml) and 0.15 ml/100 g 
body weight of the solution was delivered IP. The rodent 
dorsal skin flap window preparation first developed by 
PapenfuSS et al. was used as an in Vivo animal model to 
demonstrate the effect of glycerol on photocoagulation of 
blood vessels. This in vivo model allows the simultaneous 
observation of the epidermal and Subdermal sides of the skin 
while maintaining hydration and function PapenfuSS et al., 
1979). The preparation has been used as an in vivo model for 
optical imaging blood vessels on the Subdermal Side of skin 
while maintaining access to the epidermis Barton et al., 
1998, Vargas et al., 2001). 
The preparation includes Shaving and epilating the entire 
dorsal area of a hamster. The skin is pulled away from the 
body along the dorsal midline and Sutured to a vertical 
c-clamp. A circular region 1 cm in diameter is cut from one 
Single thickness of Skin, eXposing the Subdermal side of the 
opposing thickness of skin. An aluminum chamber is 
Sutured to both sides of the skin, and glass is placed over the 
cutout Section to prevent the tissue from dehydrating on the 
Subdermal Side. During the experiments, this glass is 
removed for improved imaging, and hydration is maintained 
with application of physiological Saline. 
Blood vessels in the skin of the dorsal window prepara 
tion are located in the Subdermal fat and connective tissue 
layers approximately 400-700 um beneath the epidermal 
surface and about 80-100 um from the exposed subdermal 
surface of a 100 g hamster. Arterioles and venules in the 
dorsal window preparation range in diameter between about 
50-500 um in inner diameter, with the main arteriole and 
venule about 350-500 um in diameter. 
In vivo Application of Glycerol 
Anhydrous glycerol was applied to the Subdermal Side of 
the dorsal skin flap window preparation. The Subdermal side 
of the window preparation contains a well approximately 2 
mm deep and 1 cm in diameter placed directly over the 
exposed Subdermal skin. A Small opening at the bottom 
allows the flow of glycerol out of the well. This well was 
filled with glycerol and continually refilled for a total time 
of twenty minutes. Any remaining glycerol was removed 
from the well at the end of twenty minutes. An example 
window preparation shown from the subdermal side before 
and after the application of glycerol is shown in FIG. 2. 
Subdermal Irradiations 
Subdermal irradiations allowed for the direct irradiation 
of blood vessels in the rodent dorsal skin flap window 
preparation. Direct irradiations of blood vessels following 
treatment with glycerol were performed to demonstrate the 
benefits of a decrease in blood flow velocity due to chemical 
agents. A total of 46 Venules and 38 arterioles were irradi 
ated directly in Six window preparations following applica 
tion of glycerol with radiant exposures ranging from 0.3 
J/cm° to 7.5 J/cm°. Three to six irradiations were performed 
on each window preparation depending on the anatomical 
Structure of the microvasculature. For instance, in the win 
dow preparation of FIG. 3, six areas were irradiated (shown 
by the circles) to target individual arteriole-Venule pairs. 
Venules ranged in diameter from 50 to 200 micrometers. 
Arteriole diameters ranged from 20 to 140 micrometers. 
Each arteriole-Venule pair was irradiated a Single time with 
a single pulse from a Versapulse V Vascular (Coherent, 











10 ms and Spot size of 3 mm. The window preparation was 
viewed and recorded through a Surgical microscope (Wild 
Leitz M650, Germany) prior to, during, and following 
irradiation. The window preparation was observed twenty 
four hours after laser irradiation to assess whether perma 
nent coagulation occurred for each vessel irradiated. 
Since previous Studies have revealed that the fluences 
required to permanently destroy a blood vessel depends on 
size and type (arteriole vs. venule) Kimel et al., 1994; 
Barton, 1998), data analysis for venules and arterioles was 
done separately, and for each type, vessels were categorized 
according to inner diameter. Venules were categorized in 
four groups (50-80 um, 80-110 um, 10-140 um, and 
140-200 um diameter) and arterioles into three groups 
(20-50 um, 50-80 um, and 80–110 um). 
Yes/no (0/1) grading of vessel destruction by photoco 
agulation after twenty-four hours was used to perform probit 
analysis on the data assuming a Sigmoid probability 
distribution, resulting in 50% probability for threshold radi 
ant exposures (RE50) for vessels of a given size category 
and type Cain et al., 1996). 
Epidermal Irradiations 
While the Subdermal irradiations were done to show that 
the resulting decrease in blood flow Velocity by glycerol 
allows for a Substantial decrease in laser doses to destroy 
vessels, epidermal irradiations were performed to demon 
Strate how the technique could be carried out clinically. In 
this Set of experiments, three dorsal Skin flap window 
preparations were treated with glycerol on the Subdermal 
Side of the skin. Then, the main arteriole-Venule pair (Such 
as the one labeled A and V in FIG.3) was irradiated from the 
epidermal side to determine the approximate range of radi 
ant exposures required to permanently destroy blood vessels 
in Skin treated with glycerol. Since no published data exists 
for direct comparison with controls, two native hamster 
dorsal Skin flap window preparations were irradiated from 
the epidermal side as well. 
The Skin Surrounding the main arteriole-Venute pair in 
each window preparation was first imaged using Color 
Doppler optical coherence tomography (CDOCT) (see FIG. 
5). The skin was imaged from the subdermal side since these 
blood vessels are located approximately 100 um from the 
Subdermal Surface, allowing for accurate determination of 
vessel flow and size characteristics. In the case of control 
Samples (2), the vessels were irradiated from the epidermal 
Side immediately after imaging the native skin. This was 
achieved by applying a single pulse from a 532 nm, 3 mm 
spot size, 10 ms pulse duration laser (Versapulse V, 
Coherent) to the skin without altering its position relative to 
the CDOCT sample probe. The experimental setup is illus 
trated in FIG. 5. 
The skin was imaged again to assess changes to blood 
flow. In the first control Sample, if no changes were observed 
to occur, the skin was radiated with a higher radiant expo 
Sure one hour later. If any changes in flow or vessel Size were 
observed, the Skin was not irradiated again and was imaged 
after 24 hours. In all, 5 pulses were delivered ranging in 
radiant exposure from 4.13 J/cm to 16 J/cm, the maximum 
allowable for the laser parameters used. In the Second 
control Sample, only a single pulse was delivered with a 
radiant exposure of 12 J/cm. 
In the other three Samples, glycerol was applied to the 
Subdermal Side of the window preparation for twenty min 
utes after imaging the native skin with CDOCT. The opti 
cally cleared Skin was then imaged again using CDOCT. 
Laser pulses were applied in the Same manner described 
above and the skin was re-imaged after twenty-four hours to 
assess if permanent vessel closure occurred. 




The resulting RE50 values for permanent vessel destruc 
tion are Summarized in FIG. 4 for arterioles and venules in 
skin treated with glycerol prior to irradiations. Results are 
compared to values from previously published results on 
Subdermal irradiations performed on dorsal windows not 
treated with glycerol Barton et al., 1998 in FIG. 4. Due to 
the small number of irradiations compared to the number of 
parameters (vessel size and type), there was insufficient data 
to estimate the ED50 values for arterioles and venules 
80-110 um in diameter. 
Epidermal Irradiations 
The CDOCT amplitude and Doppler images from the first 
control sample prior to irradiations are shown in FIG. 6. The 
amplitude image represents backScattered light from the 
tissue-a cross-section of the Skin is shown. The Doppler 
image represents frequency-shifted light from Scatterers in 
the skin. While one cannot identify blood vessels in the 
amplitude image, an arteriole and Venule are identified in the 
Doppler image. The arteriole (A) diameter is 225 um, and 
the venule (V) diameter is 470 um. They are located approxi 
mately 80 um from the subdermal surface (the first interface 
in the top of the amplitude scan) and 750 um from the 
epidermal Surface (not shown here). Although this sample 
was repeatedly irradiated with radiant exposures Starting at 
4.13 J/cm and ending with 16 J/cm’, twenty-four hours 
later flow remains in both vessels (FIG. 7). 
In the second control sample a single pulse (12J/cm) was 
unsuccessful in leading to permanent flow cessation of either 
an arteriole (290 um) or venule (460 um), which were 
located 500 um below the epidermal surface of the skin (100 
aim from the Subdermal Surface). 
In the three window preparations where glycerol was 
applied prior to irradiation from the epidermal side, blood 
vessels on the Subdermal Side of the skin were Successfully 
destroyed with radiant exposures as low as 1.6 J/cm’. One 
such example follows. The native skin of one rodent window 
preparation is shown in FIG.8. The arteriole diameter is 250 
lum, while the venule has a diameter of 300 lum. They are 
located 450 um from the epidermal surface. 
The same Skin is again shown after treatment with glyc 
erol for twenty minutes (FIG. 9). The Doppler image of FIG. 
9 shows that flow does not remain in either the arteriole or 
Venule. This result is typical as has been observed in a 
previous study Vargas, 2001). That study showed that flow 
cessation after the treatment with glycerol alone is not 
permanent (upon hydration the skin and blood vessels return 
to their native state). A single pulse (1.6 J/cm) was applied 
from the subdermal side of the skin in FIG. 9. Twenty-four 
hours later, flow has not returned to either vessel (FIG. 10), 
despite hydration of the skin. 
In another preparation, Successful permanent coagulation 
using glycerol was achieved using a radiant exposure of 4.13 
J/cm. In this case the vessels (200 um arteriole and 410 um 
venule) were located 680 um below the epidermal surface in 
the native skin and almost 400 um in the skin treated with 
glycerol. Finally, in the third case 4.95 J/cm applied to skin 
with a 300 um arteriole and 390 um venule, only the venule 
was Successfully coagulated. In this case, the vessels were 
located 615 um from the epidermal Surface of the native skin 
and 300 um in the glycerol-treated case. 
DISCUSSION 
Subdermal Irradiations 
Because in Subdermal irradiations, blood vessels of the 











present, the data of FIG. 4 indicates that the morphological 
effects of glycerol on cutaneous blood vessels (specifically, 
the decrease in blood flow velocity) considerably aids in 
their permanent destruction by laser radiation. Comparison 
with previously published results Barton et al., 1998 
indicate that glycerol reduces radiant exposures required for 
permanent vessel destruction by a factor of 10 for arterioles 
and a factor of 5-8 for venules. The results of this experi 
ment lead us to conclude that radiant exposures required to 
directly destroy vessels of a given type and size were 
drastically reduced by using glycerol to reduce or cause the 
cessation of blood flow in Subdermal blood vessels. 
Epidermal Irradiations 
These results appear to indicate that the techniques dis 
cussed herein allow use of lower laser fluences when treat 
ing cutaneous blood vessel lesions. The Studies of the 
inventors indicate that the decrease in laser fluences and 
increase in depth penetration of light afforded by these 
techniques may have a significant, lasting impact on the 
clinical laser treatment of cutaneous vascular lesions. 
CONCLUSION 
The presented data offers experimental Support of using 
glycerol and other “optical clearing agents that control flow 
Velocity to enhance the laser treatment of cutaneous vascular 
lesions. This method may significantly impact clinical laser 
procedures not only for the treatment of cutaneous vascular 
lesions, but also for any malady whose treatment would 
benefit from increased light penetration and the reduction in 
blood flow velocity. 
With the benefit of the present disclosure, those having 
skill in the art will comprehend that techniqueS claimed 
herein may be modified and applied to a number of 
additional, different applications, achieving the same or a 
Similar result. For example, techniques of this disclosure 
may be applied to, for example, the treatment of blood 
vessels endoscopically-as in a Stomach ulcer, etc. In Such 
an application, topical application may be achieved without 
modifying the tissue. The claims attached hereto cover all 
such modifications that fall within the scope and spirit of this 
disclosure. 
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What is claimed is: 
1. A method of treating a cutaneous vascular lesion, 
comprising: 
identifying a patient in need of vascular lesion treatment; 







Slowing blood flow velocity within the region using the 
hyperoSmotic agent; and 
exposing the lesion to laser radiation. 
2. The method of claim 1, wherein the patient is human. 
3. The method of claim 1, wherein administering com 
prises injection by a hypodermic needle or a high Velocity 
jet. 
4. The method of claim 1, wherein administering com 
prises tape Stripping, ablation, chemical peel, mechanical 
debridement, electroporation, ultrasound, or iontophoresis. 
5. The method of claim 1, wherein the hyperosmotic agent 
comprises glycerol. 
6. The method of claim 1, wherein the hyperoSmotic agent 
comprises dimethyl Sulfoxidc, Sucrose, glucose (dextrose), 
propylene glycol, polyethylene glycol, hypacue Sodium 
(diatrizoate Sodium), or mannitol. 
7. The method of claim 1, wherein the region adjacent the 
lesion overlaps the lesion. 
8. The method of claim 1, wherein slowing blood flow 
velocity comprises slowing blood flow velocity by at least 
15%. 
9. The method of claim 1, wherein the blood flow velocity 
is slowed to Zero. 
10. The method of claim 1, wherein exposing the lesion 
to laser radiation comprises exposing the lesion to an 
amount of radiation Sufficient to destroy a blood vessel, the 
amount of radiation being at least 15% less than an amount 
of radiation required to destroy a blood vessel in the absence 
of the administration of the hyperoSmotic agent. 
11. The method of claim 1, wherein exposing the lesion to 
laser radiation comprises irradiating the lesion with an 
energy per area between about 0.2J/cm and about 6.J/cm. 
12. The method of claim 1, further comprising reducing 
light reflection and refraction among cellular components 
within the region, using the hyperoSmotic agent, to enhance 
light transmission through the region. 
13. The method of claim 1, further comprising delivering 
a hydrating agent within the patient and to a region adjacent 
the lesion. 
14. The method of claim 13, wherein the hydrating agent 
comprises Saline. 
